The anti-inflammatory drug Celebrex, when taken in conjunction with low doses of aspirin, limits protections from heart attack and stroke, according to new findings.
As recently detailed in the Proceedings of the National Academy of Sciences, researchers learned in animal studies that Celebrex limits aspirin from discouraging the formation of blood clots that can lead to heart attack or stroke.
Part of a newer class of non-steroidal anti-inflammatory drugs known as COX-2 inhibitors, Celebrex, or celecoxib, works to stop the chemical reactions associated with inflammation from arthritis and other pain in the body without harming the chemical production of the protective stomach lining.
Low doses of aspirin are often used with Celebrex to counteract celecoxib from potentially promoting blood clot formation.
In the study, researchers examined the blood of animals that were given either Celebrex with low doses of aspirin or just low doses of aspirin.
According to the findings, animals that were given Celebrex and low doses of aspirin had more clumping of platelets (the initial stage of clotting) than animals that received just the aspirin.
Using biomechanical measurements and X-ray crystallography, the researchers learned that celecoxib slows aspirin’s ability to block COX-1, an enzyme that promotes blood clotting, by binding to this enzyme.
According to the researchers, these findings may suggest that aspirin be taken in higher doses or spread out over time when taken with Celebrex to discourage blood cot formation.